Transfection Solutions from Bench to Bioreactor
Whether you’re producing viral vectors at clinical and commercial scales, manufacturing recombinant proteins and monoclonal antibodies, performing knock-out studies with siRNA, or editing genes using CRISPR, we have the nucleic acid delivery system you need.
Are you getting the most from your AAV process?
Run your own analysis with our new AAV economic calculator.
Compare transfection reagents head-to-head to see how you can drive down cost per dose by optimizing your bioprocessing workflow.
Transforming the Science of Transfection since 1995
Mirus was founded in 1995 to address the limitations and risks of viral gene transfer. We developed the first pDNA transfection method that combined high efficiency with low cellular toxicity, and since that time, we’ve focused on applying intentional design to nucleic acid delivery systems.
Proven Transfection for Therapeutic Viral Vector Manufacturing
TransIT-VirusGEN® Transfection Reagent is designed to enhance delivery of packaging and transfer plasmids to adherent and suspension HEK 293 cell types to increase recombinant adeno-associated virus (AAV) and lentivirus production.
Overcoming Challenges with Viral Vector Optimization
In this podcast, listen to the first-hand account of how researchers from St. Jude overcame the challenges with viral vector optimization to produce ground-breaking gene therapy for hemophilia with the hope to start treating patients on a large-scale in 2023.